Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence

PHASE2RecruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

November 4, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Langerhans Cell Histiocytosis of Bone
Interventions
DRUG

Prednisone

For the experimental group, the patient will be administrated oral prednisone (0.5mg/kg/day, first 5 days per month, 6 months)

Trial Locations (1)

200003

RECRUITING

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
collaborator

First Affiliated Hospital of Zhejiang University

OTHER

collaborator

Peking University Third Hospital

OTHER

collaborator

National Sun Yat-sen University

OTHER

collaborator

Beijing Children's Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Tianjin Hospital

OTHER

collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Second Hospital of Jilin University

OTHER

collaborator

Peking University People's Hospital

OTHER

collaborator

Jinling Hospital, China

OTHER

collaborator

The First Affiliated Hospital of Nanchang University

OTHER

collaborator

The Third Affiliated Hospital of Southern Medical University

OTHER_GOV

lead

Shanghai Changzheng Hospital

OTHER